A synthetic peptide being developed by Bicycle Therapeutics Plc of the UK has shown promising results in a Phase 1/2 study of patients with urothelial carcinoma. The drug, BT8009, is a synthetic short peptide which is being developed for advanced solid tumours associated with Nectin-4 expression. Results for eight out of 34 patients from the study were reported at the annual meeting of the American Association for Cancer Research in April.
